NCT02800759

Effect of Cis-9-cetylmyristoleate in Sub-healthy Subjects Presenting With Knee Joint Pain

The Minimal Effective Dose of Cis-9-cetylmyristoleate (CMO) in Persons Presenting With Knee Joint Pain

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 28 (actual)
• Sponsor: Seoul National University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

Cis-9-cetylmyristoleate (CMO) is a naturally occurring fatty acid complex (FAC). Nutraceuticals containing CMO are used to improve knee pain despite the lack of placebo-controlled studies in humans. The aim of the double-blind controlled clinical trial is to explore the minimal effective dose of CMO for relieving knee joint pain.

Detailed description

Methods: Twenty-eight subjects, who are clinically or radiologically diagnosed as having mild degree arthritic knee joint pain, are randomized into 3 groups; Groups A, B, C that contained 100%, 80%, and 62.4% of fatty acid component with 12.5% of Cis-9-cetylmyristoleate (CMO), and control Group D (starch 100%). The pain intensity, functional disability state and change in the general status were assessed for a 12-week ingestion period.

Conditions

• Knee Pain Intermittent

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	JOINTRUS®	100% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate
DIETARY_SUPPLEMENT	80% dose of JOINTRUS®	80% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate
DIETARY_SUPPLEMENT	62.4% dose of JOINTRUS®	62.4% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate
DIETARY_SUPPLEMENT	Starch 100%	0% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate

Timeline

• Start date: 2013-09-01
• Primary completion: 2014-07-01
• Completion: 2014-07-01
• First posted: 2016-06-15
• Last updated: 2016-06-15